Breaking News

TrialSpark Licenses Sprifermin from Merck KGaA, Forms High Line Bio

Sprifermin promotes cartilage growth, and could be a potential disease modifying treatment for osteoarthritis.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

TrialSpark has formed High Line Bio following the acquisition of worldwide rights to sprifermin from Merck KGaA, Darmstadt, Germany. Sprifermin is a potential first-in-class disease modifying anti-FGF 18 monoclonal antibody that is being evaluated as a potential treatment for osteoarthritis (OA) by promoting cartilage growth. Cartilage loss is an important component in the development of OA, a degenerative joint disease with unmet medical needs.    As the first monoclonal antibody to demonstra...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters